{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:46:17Z","timestamp":1788903977475,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1001\/jamaoncol.2018.4070","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T03:48:49Z","timestamp":1538192929000},"page":"30","source":"Crossref","is-referenced-by-count":264,"title":["Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B"],"prefix":"10.1001","volume":"5","author":[{"given":"Jonggi","family":"Choi","sequence":"first","affiliation":[{"name":"Liver Center, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayoun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhee","family":"Cho","sequence":"additional","affiliation":[{"name":"Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jung","family":"Ko","sequence":"additional","affiliation":[{"name":"Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[{"name":"Liver Center, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"},{"name":"Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi180076r1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"coi180076r2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"10100","key":"coi180076r3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"coi180076r4","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study.","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"coi180076r5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"15","key":"coi180076r6","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"coi180076r7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"coi180076r8","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"2","key":"coi180076r9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"coi180076r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"coi180076r11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.v67.4","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"coi180076r12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"coi180076r13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cgh.2012.10.003","article-title":"Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus\u2013related cirrhosis.","volume":"11","author":"K\u00f6kl\u00fc","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"coi180076r14","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.7314\/APJCP.2012.13.12.6163","article-title":"A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea.","volume":"13","author":"Seo","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"coi180076r15","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.3390\/ijerph120505129","article-title":"Trend of suicide rates according to urbanity among adolescents by gender and suicide method in Korea, 1997-2012.","volume":"12","author":"Choi","year":"2015","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"coi180076r16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/jcph.v55.3","article-title":"A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.","volume":"55","author":"Zuo","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"coi180076r17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijid.2014.09.004","article-title":"Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-na\u00efve patients with chronic hepatitis B: a multicenter real-life study.","volume":"28","author":"Batirel","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"4","key":"coi180076r18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"coi180076r19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-?3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"issue":"7","key":"coi180076r20","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00262-010-0831-3","article-title":"Antitumor activity of type I and type III interferons in BNL hepatoma model.","volume":"59","author":"Abushahba","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"coi180076r21","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-lambda in murine tumor models.","volume":"176","author":"Sato","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"coi180076r23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1021\/tx200458s","article-title":"Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases.","volume":"25","author":"Brown","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"coi180076r24","doi-asserted-by":"publisher","first-page":"e0147440","DOI":"10.1371\/journal.pone.0147440","article-title":"Genetic evidence for genotoxic effect of entecavir, an anti-hepatitis B virus nucleotide analog.","volume":"11","author":"Jiang","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"coi180076r25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/mutage\/ger094","article-title":"Studies on genotoxicity and carcinogenicity of antibacterial, antiviral, antimalarial and antifungal drugs.","volume":"27","author":"Brambilla","year":"2012","journal-title":"Mutagenesis"},{"issue":"5","key":"coi180076r26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1073\/pnas.0305817101","article-title":"Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma.","volume":"101","author":"Wilkens","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"coi180076r27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1096\/fj.01-0977com","article-title":"Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis.","volume":"16","author":"Wiemann","year":"2002","journal-title":"FASEB J"},{"issue":"1","key":"coi180076r28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis.","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"coi180076r29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"20","key":"coi180076r30","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"coi180076r31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/ajg.2016.257","article-title":"Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE study.","volume":"111","author":"Ahn","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"coi180076r32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000096313","article-title":"Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea.","volume":"50","author":"Kim","year":"2007","journal-title":"Intervirology"},{"key":"coi180076r22","unstructured":"US Food and Drug Administration. NDA Review pharmacology\/toxicology review and evaluation: NDA No. 21-797: submitted September 30, 2004. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/21797_BARACLUDE_pharmr.PDF. Accessed August 21, 2018."}],"updated-by":[{"DOI":"10.1001\/jamaoncol.2019.0576","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"record-id":"20361"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/1\/30\/17543807\/jamaoncology_choi_2018_oi_180076_19268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T11:03:11Z","timestamp":1556190191000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4070"}},"subtitle":["A Korean Nationwide Cohort Study"],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4070","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}